Affymax, Inc. Announces Cancer-Profiling Collaboration

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix, Inc. (NASDAQ:AFFX) today announced that the company has entered into an agreement with the Broad Institute to chart the genomic changes involved in more than 20 types of cancer as part of the Broad’s work in The Cancer Genome Atlas (TCGA). The agreement will involve the processing of 13,500 cancer samples on the Affymetrix® Genome-Wide Human SNP 6.0 Array, a widely used platform for genotyping and studying copy number variation (CNV) and somatic events in tumor samples. The SNP Array 6.0 will also determine loss of heterozygosity (LOH), an important genomic change that indicates a loss of normal function that cannot be detected using traditional cytogenetic methods such as FISH or comparative genomic hybridization (CGH).

MORE ON THIS TOPIC